SCHEMBL1247590

SCHEMBL1247590

C[C@@H]1CCC[C@@]2(CO)CC[C@H]3[C@H](C)CC[C@@H](C[C@H]12)C3(C)C

nearest known ligand 0.33

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.33
MAPK14 Q16539 1/20 0.33
CAMK1D Q8IU85 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Alcohol SCHEMBL3199084 0.79 NR1I3 (0.39) RETMAPK14CAMK1D
SCHEMBL3825 0.76 CDK5 (0.40) RETMAPK14CAMK1D
SCHEMBL901326 0.76 CDK5 (0.40) RETMAPK14CAMK1D
SCHEMBL332530 0.76 CDK5 (0.40) RETMAPK14CAMK1D
Ammonia Solution, Strong SCHEMBL2074263 0.75 CDK5 (0.39) RETMAPK14CAMK1D
Water SCHEMBL1888091 0.75 CDK5 (0.39) RETMAPK14CAMK1D
SCHEMBL789094 0.75 CDK5 (0.39) RETMAPK14CAMK1D
Water SCHEMBL3935755 0.75 CDK5 (0.39) RETMAPK14CAMK1D
Water SCHEMBL1070875 0.75 CDK5 (0.39) RETMAPK14CAMK1D
SCHEMBL27882040 0.75 CDK5 (0.39) RETMAPK14CAMK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2298754-B9 Preparation of taxane derivatives INDENA SPA (IT) 2013-12-18 EP disclosed
EP-2298754-B1 Preparation of taxane derivatives INDENA SPA (IT) 2013-08-07 EP disclosed
EP-2264019-B1 Intermediates for the preparation of taxane derivatives INDENA SPA (IT) 2013-07-24 EP disclosed
EP-2077264-B1 Taxane derivatives and a process for the preparation thereof INDENA SPA (IT) 2012-11-14 EP disclosed
EP-2298754-A1 Preparation of taxane derivatives Indena S.p.A. (IT) 2011-03-23 EP disclosed
EP-2281820-A2 Taxane derivatives and a process for the preparation thereof Indena S.p.A. (IT) 2011-02-09 EP disclosed
EP-2264019-A1 Intermediates fot the preparation of taxane derivatives Indena S.p.A. (IT) 2010-12-22 EP disclosed
EP-2077264-A2 Taxane derivatives and a process for the preparation thereof INDENA S.p.A. (IT) 2009-07-08 EP disclosed
US-7498452-B2 Taxane derivatives functionalized at the 14-position and a process for the preparation thereof INDENA S.P.A. (IT) 2009-03-03 US disclosed
EP-1980557-A2 Taxane derivatives functionalized at the 14-position and a process for the preparation thereof Indena S.P.A. (IT) 2008-10-15 EP disclosed
EP-1537093-B1 TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF INDENA SPA (IT) 2008-06-11 EP disclosed
US-20060122258-A1 Taxane derivatives functionalized at the 14-position and a process for the preparation thereof INDENA S.P.A. (IT) 2006-06-08 US disclosed
EP-1537093-A2 TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF INDENA S.p.A. (IT) 2005-06-08 EP disclosed
WO-2004024706-A2 TAXANE DERIVATIVES FUNCTIONALIZED AT THE 14- POSITION AND A PROCESS FOR THE PREPARATION THEREOF INDENA S.P.A. (IT) 2004-03-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122258-A1 Taxane derivatives functionalized at the 14-position and a process for the preparation thereof TUBA1B, TUBB2B, TUBB3 RET 1846/4885MAPK14 88/4885CAMK1D 3460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.